Autologous Bone Marrow Transplantation - Blog Science Connections

678 Peripheral Stem Cell Transplantation
Regimen 5
Melphalan (200 mg/m 2 ) (patient 7).
ABSCT was performed 48 hours after completion of chemotherapy in
regimens 1 and 3 and 24 hours after chemotherapy in regimens 2,4, and 5.
In Vitro Stem Ceil Assay
To determine the concentration of hematopoietic progenitor cells in
each harvested cell suspension and in the peripheral blood before and after
ABSCT, we used the human multilineage in vitro assay in methylcellulose—
the human pluripotent stem cell (CFCJ-GEMM) assay—previously described
by Fauser and Messner (23) and modified according to Ash et al. (24).
RESULTS
Blood Stem Cell Collection
Stem Cell Yield in Seven Patients Pretreated and
Infused With Transplanted Blood Stem Cells
Subsequently
Patients had received various chemotherapeutic regimens before stem
cell apheresis was started.
In patient 1, who had non-Hodgkin's lymphoma, seven aphereses were
performed from 2 to 4 weeks after the conclusion of chemotherapy with
cyclophosphamide, vincristine (Oncovin), methotrexate, and prednisone
(COMP).
Patient 2, who had recurrent Hodgkin's disease, was heavily pretreated
with radiation and polychemotherapy (6 x cyclophosphamide, Oncovin,
prednisone, procarabazine [COPP]; 1 x cyclophosphamide, hydroxydaunomycin
[Adriamycin], Oncovin, prednisone [CHOP]; 6 x Adriamycin, bleomycin,
vinblastine, dacarbazine [ ABVD]) and, after his third relapse, received
three cycles of hydroxydaunomycin (Adriamycin), Oncovin (vincristine), ara-
C (cytarabine), prednisone, and bleomycin (HOAP-Bleo). Aphereses were
performed early in the fourth remission (four runs 3-4 weeks after the first
cycle of HOAP-Bleo and five runs 2-3 weeks after cyclophosphamide [15
mg/kg x 4 days] administered 4 weeks after the third cycle of HOAP-Bleo).
Patient 3, who had end-stage acute myelogenous leukemia (AML), was
pretreated with two courses of 6-thioguanine, ara-C (cytarabine), and
daunorubicin (TAD), two courses of amsacrine, two courses of mitoxantrone/VP-16-213
(etoposide), and one course of high-dose ara-C. Stem cells
were collected by seven aphereses early in the third complete remission (CR),
3-5 weeks after the completion of the last cytotoxic treatment (second course
of mitoxantrone/etoposide).
Patient 4 had sarcoma (Askin tumor). Treatment consisted of four cycles
of vincristine, Adriamycin, ifosfamide, and actinomycin D (VAIA). Eight